Skip to content

Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic

Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04404244
Acronym
PedCan-COVID
Enrollment
800
Registered
2020-05-27
Start date
2020-01-01
Completion date
2024-01-01
Last updated
2024-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus COVID-19

Brief summary

This is a prospective follow-up non-intervention study that will be carried out at Hematology/ Oncology Department, Children's hospital, Ain-Shams University, Cairo, Egypt. All followed-up children below 18 years with cancer during the one year study period from May 2020 till Apr 2021 either at the out-patients clinic or inpatient department will be recruited.

Detailed description

Study Procedures: On admission or during the outpatient visit: 1. Obtaining an informed consent . 2. Full medical history, concurrent medications, demographic data and epidemiological data (history of contact to a COVID-19 case, history of travel), will be obtained. 3. A thorough physical examination will be performed. 4. Body weight, height, BMI, vital signs (blood pressure, heart rate and temperature) and blood oxygen saturation) will be recorded. 5. Laboratory to perform the following tests: Complete blood count with differential counts, COVID -19 reverse Transcription Polymerase Chain Reaction (RT-PCR) test by nasopharyngeal swab. During admission: Whenever unexplained fever and or respiratory symptoms developed or whenever COVID19 suspected to have the following to be performed: 1. Symptom developed that necessitates to repeat oropharyngeal and nasopharyngeal swab if indicated will be collected 2. Chest X-ray or CT chest will be recorded. 3. Laboratory to perform the following tests: Complete blood count with differential counts, COVID-19 RT-PCR test by oropharyngeal and nasopharyngeal swab: C-reactive protein and serum ferritin level. Coagulation test; D. dimer, prothrombin time and INR. Routine bacteriological study, blood culture and other symptoms/signs based cultures will be recorded On discharge: * Date of discharge * Period of admission * Period of fever * A thorough physical examination will be performed * Record the outcome

Interventions

None listed

Sponsors

Fatma Soliman Elsayed Ebeid, MD
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Children below 18 years with malignancy either hematological or solid tumors or 2. Children below 18 years with hematological condition

Exclusion criteria

1\. Patients or care-givers refusal to be enrolled in the study

Design outcomes

Primary

MeasureTime frameDescription
Incidence of COVID-19 among children with cancer12 monthsMeasure the incidence of COVID-19 infection among children with cancer

Secondary

MeasureTime frameDescription
Families training12 monthsFamilies training about adhering to standard precautions for basic and respiratory hygiene to reduce the risk of transmission

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026